OakChart

Dare Bioscience Inc

DAREHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

0.6941+0.0020 (0.29%)
2026-11-12 02:19 CET
Market cap
13.61 USD m
Revenue, TTM
1.37 USD m
Net income, TTM
-10.99 USD m
Free cash flow, TTM
-11.76 USD m
EPS diluted, TTM
-0.79
P/E
-
Compare

Price

DARE against its 20, 50 and 200-day averages
2050200beatearnings
1.002.003.004.0M8.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26DAREclose 0.6920-day 0.6850-day 0.73200-day 1.530.69

81.6% under the 52-week high of 3.78 on 5 May 2026. 52-week low 0.61 on 5 Nov 2026. Last 15 sessions, 21.1% high to low

Volume 0.19× normal · the line is the 50-bar volume average

Profile

DARE
52-week range, 3% of the way up
0.613.78

Dare Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley on November 28, 2005 and is headquartered in San Diego, CA.

Employees24
IPOApr 10, 2014
Beta1.14
ATR, 14d0.05
Rel volume0.19
Short float5.68%
Insider own11.72%
Inst own13.97%

Snapshot

6 groups

Valuation

Index-
Market Cap13.65M
Enterprise Value7.79M
Income-10.99M
Sales1.37M
Book/sh-0.04
Cash/sh0.64
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees24
IPOApr 10, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S9.96
P/B-
P/C1.08
P/FCF-
EV/EBITDA-
EV/Sales5.69
Quick Ratio0.99
Current Ratio0.99
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.79
EPS next Y-0.51
EPS next Q-0.13
EPS this Y38.61%
EPS next Y30.77%
EPS next 5Y46.87%
EPS past 3/5Y35.13% 35.73%
Sales past 3/5Y-53.12% -
EPS Y/Y TTM-82.83%
Sales Y/Y TTM-
EPS Q/Q55.76%
Sales Q/Q985.82%
EarningsNov 16 AMC
EPS/Sales Surpr.32.59% 10929.41%

Ownership

Insider Own11.72%
Insider Trans0.00%
Inst Own13.97%
Inst Trans7.87%
ROA-62.16%
ROE-
ROIC-201.69%
Gross Margin-128.01%
Oper. Margin-813.38%
Profit Margin-804.37%
SMA202.76%
SMA50-5.13%
SMA200-54.61%
Trades-

Technical

Shs Outstand19.67M
Shs Float17.36M
Short Float5.68%
Short Ratio1.95
Short Interest0.99M
52W High3.78 -81.64%
52W Low0.61 13.79%
Volatility6.16% 6.55%
ATR (14)0.05
RSI (14)48.19
Beta1.14
Rel Volume0.19
Avg Volume506.02K
Volume97,954

Performance

Perf Week4.86%
Perf Month-7.17%
Perf Quarter-49.34%
Perf Half Y-75.56%
Perf YTD-64.04%
Perf Year-64.22%
Perf 3Y-82.47%
Perf 5Y-96.49%
Perf 10Y-99.30%
Recom1.00
Target Price6.33
Prev Close0.69
Price0.69
Change %0.29%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Oct 26, 2026InitiatedLLadenburg ThalmannBuy$2+188.1%

Peers

Mkt cap
TickerCompanyMkt cap
PTNPalatin Technologies Inc12.22M
FEMYFemasys Inc12.57M
LPCNLipocine Inc17.61M
TXMDTherapeuticsMD Inc21.41M
OGNOrganon & Co3.65B
VERUVeru Inc36.49M
LFMDLifeMD Inc85.80M
HIMSHims & Hers Health Inc4.86B
IVFINVO Fertility Inc3.21M
MGRXMangoceuticals Inc4.42M

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 100
  • Dare Bioscience Faces Its Delivery Quarter As Dare To Play Timing And Cash Take Center Stage (Earnings Whispers)
  • Dare Bioscience to Host Third Quarter 2026 Financial Results and Company Update Conference Call and Webcast on November 16, 2026 (GlobeNewswire)
  • Dare Bioscience Releases Next Episode in "CEO Corner" Video Series (GlobeNewswire) +6.42%
  • Dare Bioscience to Present at Stifel's 2026 Healthcare Conference (GlobeNewswire)
  • Dare Bioscience Surpasses $43 Million in Non-Dilutive Grant Funding as Investigational Programmable Drug Delivery Platform Gains Momentum (GlobeNewswire)
  • Dare Bioscience Addresses New National Focus on Women's Health in Virtual Investor "What This Means" Discussion (GlobeNewswire)
  • Dare Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly (GlobeNewswire)
  • Dare Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer (GlobeNewswire)
  • Dare Bioscience Launches "CEO Corner" Video Series to Highlight the Company's Pipeline of Women's Health Innovations, Corporate Strategy and Opportunities (GlobeNewswire)
  • Dare Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting (GlobeNewswire)
  • Dare Bioscience stock rises after receiving HPV treatment patent (Investing.com)
  • Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection (GlobeNewswire)
  • Dare Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil (GlobeNewswire)
  • Dare Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-16--0.127--2.043
2026Q22026-08-13-0.200-0.297-0.2000.190.003
2026Q12026-05-14-0.200-0.305-0.2070.150.032
2025Q42026-03-260.030-0.440-0.0991.020.752
2025Q32025-11-13-0.280-0.384-0.2790.000.014
2025Q22025-08-14-0.450-0.580-0.453-0.020.284
2025Q12025-05-13-0.500-0.580-0.5000.030.603
2024Q42025-03-31-0.610-0.530-0.640-0.061.334
2024Q32024-11-14-0.550-0.685-0.5510.041.044
2024Q22024-08-121.520-0.0391.5230.027.864
2024Q12024-05-14-0.840-0.720-0.8070.010.262
2023Q42024-03-28-0.840-1.080-0.6071.872.385
2023Q32023-11-09-1.093-1.176-1.0941.000.735
2023Q22023-08-10-1.200-1.180-1.2170.001.106
2023Q12023-05-11-1.080-1.200-1.1290.001.673
2022Q42023-03-30-2.280-1.640-2.2550.000.006

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-11.640-11.250-11.5950.000.00
2020FY-10.920-9.820-10.9300.000.65
2021FY-7.560-7.032-7.5930.001.67
2022FY-4.440-3.800-4.39110.0010.00
2023FY-4.200-4.464-4.1462.813.38
2024FY-0.480-0.350-0.4770.011.08
2025FY-1.200-1.670-1.2001.030.75
2026FY--0.737--2.75
2027FY--0.510--7.40
2028FY--0.180--18.94
2029FY-0.510--45.10
2030FY-3.100--135.7

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-283002.040.005.91
2026Q3S2026-10-234101.570.005.91
2026Q3S2026-08-143102.020.005.91
2026Q3S2026-08-133001.820.005.32
2026Q3S2026-07-293001.820.005.32
2026Q3S2026-07-043011.820.005.32
2026Q3S2026-05-153021.820.005.32
2026Q3S2026-04-092010.080.000.16
2026Q3S2026-04-082010.080.000.16
2026Q3S2026-03-271000.000.000.00
2026Q3S2025-12-1220015.740.2831.20
2026Q3S2025-12-0120015.720.2831.16
2026Q3S2025-11-1720015.740.2831.20
2026Q3S2025-11-1420015.740.2831.20

Estimate history

EPS, annual-42.72-18.716-11.595-10.93-7.593-4.391-4.146-0.477-1.199-0.7856
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.8071.523-0.551-0.5-0.453-0.279-0.099-0.207-0.2
PeriodQ1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual00000102.8080.011.031.37
Period201720182019202020212022202320242025TTM
Sales, quarterly0.0090.0220.0420.025-0.0210.0021.0240.1520.188
PeriodQ1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.5040.9521.643.4666.9957.0698.3318.714.515.17
Period201720182019202020212022202320242025MRQ
Shares, quarterly8.3828.5468.5468.859.0313.9314.514.5615.17
PeriodQ1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1.371.030.012.8110.000.000.000.000.00
Cost of Goods Sold Incl. D&A3.112.450.510.040.050.030.040.010.00
Gross Profit-1.75-1.42-0.502.779.95-0.03-0.04-0.01-0.00
Selling, General and Administrative Excl. Other9.3612.1422.9533.6141.2439.0427.3614.3311.69
Research and Development0.993.8914.2621.5430.0430.6220.778.556.41
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-11.11-13.55-23.45-30.84-31.29-39.07-27.40-14.34-11.69
Interest Expense0.810.820.86-0.00--0.000.00
Unusual Expense0.000.000.000.100.10-0.370.000.005.19
Net Income Before Taxes-10.99-13.40-4.05-30.16-30.95-38.70-27.40-14.26-16.74
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-10.99-13.40-4.05-30.16-30.95-38.70-27.40-14.26-16.74
Net Income From Continuing Operations-10.99-13.40-4.05-30.16-30.95-38.70-27.40-14.26-16.74
Net Income-10.99-13.40-4.05-30.16-30.95-38.70-27.41-15.05-16.74
EPS (Recurring)-0.74-1.20-0.48-4.14-4.38-7.64-10.93-11.60-14.66
EPS (Basic, Before Extraordinaries)-0.79-1.20-0.48-4.15-4.39-7.59-10.93-11.60-18.72
EPS (Diluted)-0.79-1.20-0.48-4.15-4.39-7.59-10.93-11.60-18.72
EBITDA-8.57-11.40-22.94-30.80-31.24-39.04-27.36-14.33-11.69
Non-Operating Income (Expense)0.930.9820.260.780.440.000.000.080.14
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.501.502.202.532.161.600.740.460.14
Price To Sales Ratio23.0020.942,709.749.617.02----
Gross Margin-128.01-137.55-5,146.6198.6399.52----
Operating Margin-813.38-1,315.51-239,692.20-1,098.33-312.85----
Net Margin-804.37-1,300.66-41,430.90-1,074.17-309.48----
Shares Outstanding15.1714.508.708.337.077.003.471.640.95
Market Capitalization13.6113.6127.1530.3769.67167.8955.7416.148.12

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q32024Q2
Total Revenue0.190.151.020.00-0.020.030.040.02
Cost of Goods Sold Incl. D&A0.740.800.960.610.590.280.010.02
Gross Profit-0.55-0.640.06-0.61-0.61-0.260.030.01
Selling, General and Administrative Excl. Other2.422.351.533.063.224.324.697.34
Research and Development0.110.110.090.690.972.302.664.91
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.97-3.00-1.47-3.67-3.83-4.58-4.66-7.33
Interest Expense0.190.200.210.210.27---
Unusual Expense0.000.000.000.000.000.000.030.03
Net Income Before Taxes-2.98-3.00-1.44-3.56-4.02-4.38-4.7012.91
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-2.98-3.00-1.44-3.56-4.02-4.38-4.7012.91
Net Income From Continuing Operations-2.98-3.00-1.44-3.56-4.02-4.38-4.7012.91
Net Income-2.98-3.00-1.44-3.56-4.02-4.38-4.7012.91
EPS (Recurring)-0.20-0.21-0.10-0.28-0.45-0.50-0.551.53
EPS (Basic, Before Extraordinaries)-0.20-0.21-0.10-0.28-0.45-0.50-0.551.53
EPS (Diluted)-0.20-0.21-0.10-0.28-0.45-0.50-0.551.52
EBITDA-2.26-2.44-0.80-3.06-3.24-4.30-4.65-7.32
Non-Operating Income (Expense)0.180.200.240.320.080.20-0.0220.27
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.290.460.360.400.360.380.520.56
Price To Sales Ratio23.0022.8427.16---14.7012.04
Gross Margin-294.44-422.765.75-26,993.902,874.71-1,009.1276.6331.20
Operating Margin-1,582.53-1,967.07-143.72-162,340.7618,079.54-18,016.75-11,168.72-32,687.70
Net Margin-1,590.42-1,967.72-140.84-157,505.1318,970.73-17,219.13-11,279.4257,539.25
Shares Outstanding15.1714.5614.5013.939.038.858.558.55
Market Capitalization13.6526.5027.5828.3121.1525.1427.6933.81

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments24.7115.7010.4834.6751.674.674.786.817.56
Short Term Receivables0.570.230.951.701.150.460.560.030.28
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.782.526.126.672.481.851.110.400.51
Total Current Assets27.0618.4517.5443.0455.306.986.447.248.35
Net Property, Plant & Equipment4.402.541.980.520.240.280.550.010.00
Total Investments and Advances0.300.300.340.000.000.000.000.000.00
Intangible Assets----0.000.000.000.005.19
Other Assets0.710.811.430.260.270.290.450.580.72
Total Assets32.4722.1021.2843.8355.817.557.447.8314.26
Short Term Debt Incl. Current Port. of LT Debt2.110.550.470.400.270.710.410.000.00
Accounts Payable1.201.463.392.032.101.021.080.460.31
Other Current Liabilities20.3819.6016.6329.2013.685.924.120.630.66
Total Current Liabilities23.6921.6120.4831.6216.057.665.611.090.97
Long Term Debt5.955.504.850.090.000.040.390.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.001.001.001.001.001.001.000.010.00
Total Liabilities29.6328.1126.3332.7117.058.707.001.100.97
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity2.84-6.01-5.0511.1138.75-1.150.446.7313.29
Total Shareholders Equity2.84-6.01-5.0511.1138.75-1.150.446.7313.29
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity2.84-6.01-5.0511.1138.75-1.150.446.7313.29
Total Liabilities & Stockholders Equity32.4722.1021.2843.8355.817.557.447.8314.26
Book Value Per Share0.20-0.69-0.611.575.54-0.330.277.0726.38
Tangible Book Value Per Share0.20-0.69-0.611.575.54-0.330.277.0716.08
Full-Time Employees24232630282319145
Price to Book Ratio-18.72-17.96-13.272.644.33-48.4036.611.210.58
Return on Assets-49.10-18.69-92.65-62.12-122.15-365.50-186.82-151.57-44.29
Return on Equity---994.69-124.12-205.82--398.02-167.23-87.13
Return on Invested Capital-152.46---276.26-99.85--1,717.74-248.84-86.54
Quick Ratio1.140.850.861.363.440.911.156.648.64
Current Ratio1.140.850.861.363.440.911.156.648.64

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-10.99-13.40-4.05-30.16-30.95-38.70-27.41-14.26-16.74
Depreciation2.922.150.510.040.050.030.040.010.00
Other Funds (Non Cash)1.491.573.122.612.111.180.590.235.83
Funds from Operations-6.58-9.68-0.42-27.51-28.79-37.49-26.78-14.02-10.90
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-4.71-0.215.89-11.3410.708.731.540.710.63
Cash from Operating Activities-11.29-9.895.47-38.86-18.09-28.76-25.23-13.32-10.27
Capital Expenditures-0.46-0.39-0.57-0.63-0.06-0.01-0.020.00-0.01
Net Assets From Acquisitions0.000.000.000.000.000.000.00--0.51
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.006.14-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.46-0.39-0.57-0.63-0.06-0.01-0.026.14-0.52
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock21.8120.930.4510.651.3475.8524.765.1510.11
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock21.8120.930.4510.651.3475.8524.765.1510.11
Proceedsfrom Stock Options21.8120.930.459.351.2275.311.790.0010.11
Issuance or Reduction of Debt, Net-1.21-0.39-0.104.990.000.000.370.000.00
Change in Long Term Debt-1.21-0.39-0.104.990.000.000.370.000.00
Issuance of Long Term Debt0.170.170.485.330.000.000.370.000.00
Reduction of Long Term Debt-1.37-0.55-0.58-0.330.000.000.000.000.00
Net Financing Active Other Cash Flow-1.29-1.260.000.000.000.000.000.000.00
Other Financing Activities Uses-1.29-1.260.000.000.000.000.000.000.00
Cash from Financing Activities19.3119.280.3515.641.3475.8525.135.1510.11
Exchange Rate Effect0.030.01-0.07-0.01-0.20-0.060.01-0.01-0.08
Net Change in Cash7.589.015.19-23.86-17.0047.00-0.11-2.03-0.75
Free Cash Flow-11.76-10.274.90-39.49-18.15-28.78-25.25-13.32-10.28
Preferred Dividends (Cash Flow)-0.000.000.000.000.00--0.00
Price to Free Cash Flow--5.41------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments12.6218.5224.7123.085.0410.33
Short Term Receivables0.060.290.570.370.190.11
Inventories0.000.000.000.000.000.00
Other Current Assets4.012.851.781.561.381.39
Total Current Assets16.6921.6627.0625.006.6011.82
Net Property, Plant & Equipment3.133.734.404.735.315.72
Total Investments and Advances0.300.300.300.300.300.30
Other Assets2.252.140.710.720.770.78
Total Assets22.3727.8332.4730.7512.9818.62
Short Term Debt Incl. Current Port. of LT Debt0.761.212.112.492.612.41
Accounts Payable0.761.231.201.841.761.88
Other Current Liabilities15.4018.6820.3816.8814.8516.89
Total Current Liabilities16.9221.1223.6921.2219.2221.19
Long Term Debt6.015.975.955.675.495.99
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.001.001.001.00
Total Liabilities22.9327.0929.6327.8925.7128.18
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-0.560.732.842.86-12.73-9.56
Total Shareholders Equity-0.560.732.842.86-12.73-9.56
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-0.560.732.842.86-12.73-9.56
Total Liabilities & Stockholders Equity22.3727.8332.4730.7512.9818.62
Book Value Per Share-0.040.050.200.21-1.41-1.08
Tangible Book Value Per Share-0.040.050.200.21-1.41-1.08
Full-Time Employees--24---
Price to Book Ratio-18.779.289.41-1.49-2.21-16.64
Return on Assets-62.16-51.76----
Return on Invested Capital-54.76-44.71-16.40-41.76--
Quick Ratio0.991.031.141.180.340.56
Current Ratio0.991.031.141.180.340.56

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-2.98-3.00-1.44-3.56-4.02-4.38
Depreciation0.830.551.050.480.340.28
Other Funds (Non Cash)0.440.60-0.270.720.740.38
Funds from Operations-1.71-1.85-0.66-2.36-2.94-3.71
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-5.06-3.672.101.92-2.48-1.76
Cash from Operating Activities-6.78-5.521.44-0.44-5.42-5.47
Capital Expenditures-0.080.00-0.21-0.170.15-0.16
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.080.00-0.21-0.170.15-0.16
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)--0.000.000.000.00
Change in Capital Stock1.400.391.2718.740.480.44
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.400.391.2718.740.480.44
Proceedsfrom Stock Options1.400.391.2718.740.480.44
Issuance or Reduction of Debt, Net-0.45-1.080.41-0.09-0.52-0.19
Change in Long Term Debt-0.45-1.080.41-0.09-0.52-0.19
Issuance of Long Term Debt0.000.00-0.320.490.000.00
Reduction of Long Term Debt-0.45-1.080.74-0.58-0.52-0.19
Net Financing Active Other Cash Flow0.00-0.03-1.260.000.000.00
Other Financing Activities Uses0.00-0.03-1.260.000.000.00
Cash from Financing Activities0.95-0.720.4218.65-0.040.25
Exchange Rate Effect0.000.04-0.030.010.010.01
Net Change in Cash-5.90-6.191.6418.04-5.29-5.37
Free Cash Flow-6.86-5.521.24-0.62-5.26-5.63

Revenue breakdown

Royalty2024: 9.78K
Total Pharmaceutical Preparations revenue2025: 1.03M
United States2024: 9.78K 2025: 1.03M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.68%1.0M17.4M499.61K
2026-10-156.59%1.1M17.4M518.61K
2026-09-305.35%0.9M17.2M523.20K
2026-09-154.99%0.9M17.2M505.85K
2026-08-315.94%1.0M16.5M487.17K
2026-08-14-1.2M-432.35K
2026-07-316.17%0.8M13.6M395.88K
2026-07-154.41%0.6M13.6M639.91K
2026-06-305.07%0.7M13.6M625.48K
2026-06-155.20%0.7M13.8M612.61K
2026-05-296.01%0.8M13.7M599.88K
2026-05-155.76%0.8M13.7M566.48K
2026-04-302.68%0.4M13.4M358.26K
2026-04-151.27%0.2M13.4M84.71K
2026-03-311.59%0.2M13.3M84.24K
2026-03-131.64%0.2M13.1M102.77K
2026-02-272.22%0.3M13.1M153.74K
2026-02-132.24%0.3M13.1M154.29K
2026-01-302.37%0.3M13.1M159.81K
2026-01-152.76%0.4M13.1M185.34K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-27DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-06DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-06SEC
2026-10-028-KCurrent report2026-09-28SEC
2026-10-018-KCurrent report2026-10-01SEC
2026-09-23PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-23SEC
2026-09-118-KCurrent report2026-09-10SEC
2026-09-098-KCurrent report2026-09-09SEC
2026-09-04424B3SEC
2026-09-03EFFECTEffectiveness filing by commission orderSEC
2026-08-28SCHEDULE 13GSEC
2026-08-26S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-08-24SCHEDULE 13GSEC
2026-08-20DNotice of sales of securities on Form D (Regulation D)SEC
2026-08-19253G2SEC
2026-08-178-KCurrent report2026-08-14SEC
2026-08-17424B5SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-248-KCurrent report2026-07-24SEC
2026-07-17253G2SEC
2026-07-178-KCurrent report2026-07-13SEC
2026-07-138-KCurrent report2026-07-13SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-06-23S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-06-228-KCurrent report2026-06-22SEC
2026-06-128-KCurrent report2026-06-11SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC4.28%
UBS Group AG1.22%
US BANCORP \DE\1.12%
GEODE CAPITAL MANAGEMENT, LLC0.77%
VANGUARD FIDUCIARY TRUST CO0.61%
BlackRock, Inc.0.43%
STATE STREET CORP0.32%
JANE STREET GROUP, LLC0.24%
NORTHERN TRUST CORP0.23%
HRT FINANCIAL LP0.15%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.15%
VANGUARD EXTENDED MARKET INDEX FUND1.08%
Fidelity Extended Market Index Fund0.45%
iShares Micro-Cap ETF0.30%
Fidelity Series Total Market Index Fund0.12%
Fidelity Total Market Index Fund0.08%
VANGUARD BALANCED INDEX FUND0.05%
Fidelity Nasdaq Composite Index Fund0.05%
1290 VT Micro Cap Portfolio0.02%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. DARE. Cached 15 minutes.

Some panels did not load: insider.